Focused On-demand Library for tRNA-dihydrouridine(20) synthase [NAD(P)+]-like

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q9NX74

UPID:
DUS2L_HUMAN

ALTERNATIVE NAMES:
Dihydrouridine synthase 2; Up-regulated in lung cancer protein 8; tRNA-dihydrouridine synthase 2-like

ALTERNATIVE UPACC:
Q9NX74; A8K3G3; Q4H4D9

BACKGROUND:
The enzyme tRNA-dihydrouridine(20) synthase [NAD(P)+]-like, known alternatively as Dihydrouridine synthase 2 and Up-regulated in lung cancer protein 8, is pivotal in tRNA modification. It facilitates the NADPH-dependent synthesis of dihydrouridine within the D-loop of most tRNAs and serves as a negative regulator for EIF2AK2/PKR activation. This dual function underscores its critical role in the regulation of protein synthesis and cellular response to stress.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of tRNA-dihydrouridine(20) synthase [NAD(P)+]-like unveils potential avenues for therapeutic intervention. Given its significant role in tRNA modification and cellular stress response, targeting this enzyme could offer novel strategies for treating related pathological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8331 of 8789